Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Buy
55
CPRX Quote, Financials, Valuation and Earnings
Last price:
$21.26
Seasonality move
:
6.88%
Day range:
$21.01 - $21.41
52-week range:
$13.12 - $24.27
Dividend yield:
0%
P/E ratio:
18.03x
P/S ratio:
5.63x
P/B ratio:
3.84x
Volume:
1.7M
Avg. volume:
1M
1-year change:
48.74%
Market cap:
$2.5B
Revenue:
$398.2M
EPS (TTM):
$1.18
Analysts' Opinion
-
Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Catalyst Pharmaceuticals has an estimated upside of 51.62% from its current price of $21.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $21.27.
Fair Value
-
According to the consensus of 0 analysts, Catalyst Pharmaceuticals has 51.62% upside to fair value with a price target of -- per share.
CPRX vs. S&P 500
-
Over the past 5 trading days, Catalyst Pharmaceuticals has overperformed the S&P 500 by 1.5% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Catalyst Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Catalyst Pharmaceuticals has grown year-over-year revenues for 16 quarters straight. In the most recent quarter Catalyst Pharmaceuticals reported revenues of $128.7M.
Earnings Growth
-
Catalyst Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Catalyst Pharmaceuticals reported earnings per share of $0.35.
Enterprise value:
2.1B
EV / Invested capital:
3.17x
Price / LTM sales:
5.63x
EV / EBIT:
12.04x
EV / Revenue:
4.55x
PEG ratio (5yr expected):
0.14x
EV / Free cash flow:
9.44x
Price / Operating cash flow:
11.68x
Enterprise value / EBITDA:
9.91x
Gross Profit (TTM):
$397.5M
Return On Assets:
23.73%
Net Income Margin (TTM):
31.01%
Return On Equity:
27.81%
Return On Invested Capital:
27.81%
Operating Margin:
39.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $191.8M | $348.4M | $460.5M | $102.7M | $128.7M | |
| Gross Profit | $161.2M | $301M | $397.5M | $88.5M | $109.4M | |
| Operating Income | $83.8M | $75.9M | $174M | -$37.2M | $50.9M | |
| EBITDA | $84.4M | $100.3M | $211.4M | -$28.6M | $60.4M | |
| Diluted EPS | $0.61 | $0.52 | $1.18 | -$0.29 | $0.35 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $143.3M | $192.8M | $276.3M | $192M | $539M | |
| Total Assets | $174.9M | $223.2M | $333.1M | $413.2M | $772M | |
| Current Liabilities | $18.2M | $20.6M | $44.7M | $57.8M | $105.4M | |
| Total Liabilities | $18.2M | $24.6M | $63.1M | $64.7M | $111.1M | |
| Total Equity | $156.6M | $198.7M | $270M | $348.5M | $660.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $95.1M | $128M | $224.6M | $45.1M | $72.9M | |
| Cash From Investing | $9.2M | -$255.2M | -$38.8M | -$92.8M | -$259K | |
| Cash From Financing | -$3.1M | -$7.9M | $135.6M | -$10.1M | -$6M | |
| Free Cash Flow | $95.1M | $48.6M | $221.8M | -$34.2M | $72.6M | |
CPRX
Sector
Market Cap
$2.5B
$44.6M
Price % of 52-Week High
87.64%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-5.93%
-0.68%
1-Year Price Total Return
48.74%
-29.09%
Beta (5-Year)
0.748
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$21.56
200-day SMA
Buy
Level
$18.26
Bollinger Bands (100)
Buy
Level
19.14 - 22.14
Chaikin Money Flow
Buy
Level
6.2M
20-day SMA
Sell
Level
$21.76
Relative Strength Index (RSI14)
Sell
Level
45.60
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-80.4035
50-day SMA
Sell
Level
$21.71
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
270M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (15.3219)
Buy
CA Score
(Annual)
Level (2.2711)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-4.5395)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Stock Forecast FAQ
In the current month, CPRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPRX average analyst price target in the past 3 months is --.
-
Where Will Catalyst Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Catalyst Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Catalyst Pharmaceuticals?
Analysts are divided on their view about Catalyst Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Catalyst Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Catalyst Pharmaceuticals's Price Target?
The price target for Catalyst Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CPRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Catalyst Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CPRX?
You can purchase shares of Catalyst Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Catalyst Pharmaceuticals shares.
-
What Is The Catalyst Pharmaceuticals Share Price Today?
Catalyst Pharmaceuticals was last trading at $21.26 per share. This represents the most recent stock quote for Catalyst Pharmaceuticals. Yesterday, Catalyst Pharmaceuticals closed at $21.27 per share.
-
How To Buy Catalyst Pharmaceuticals Stock Online?
In order to purchase Catalyst Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Lucid vs Rivian Stock: Which Is Best?
Few realize that Lucid Group (NASDAQ: LCID) traces part of…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
